- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01137214
Outcome and Treatment of Complex Sleep Apnea
The purpose of the project is:
- to determine the incidence of complex sleep apnea
- to determine what percentage of cases will resolve over time with therapy with Continuous Positive Airway Pressure
- Determine whether there is any difference in outcome, in those with persistent complex sleep apnea on CPAP, between those treated with CPAP or adaptive servo-ventilation.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients with suspected obstructive sleep apnea (OSA) are studied overnight in a sleep laboratory, as part of their routine clinical management. If they are found to have OSA during the first half of the night, they are started on continuous positive airway pressure (CPAP) by nasal mask as part of their routine clinical management. A certain percentage of these patients (best estimate from the literature 15%) will develop central sleep apnea (CSA) during their treatment with CPAP.
Participants will be recruited from patients treated with Continuous Positive Airway Pressure (CPAP) for obstructive sleep apnea who develop central sleep apnea (CSA) on CPAP, and are willing to give informed consent .
Patients will be treated with the "best CPAP" pressure, as determined by the sleep physician reading their sleep study. This is defined as the minimum pressure associated with elimination of obstructive events. Patients will be treated with CPAP for 12 weeks. Following treatment, patients will be brought back for a second sleep study to be assessed on CPAP.
Those that demonstrate resolution of CSA on the sleep study will continue on CPAP for an additional 12 weeks. Those that demonstrate persistent CSA will be randomized to either "best CPAP" or Adaptive Servo-ventilation (ASV) therapy for an additional 12 weeks. ASV will be titrated during the second sleep study to determine optimal settings. Patients will be compared at the end of 12 and 24 weeks of treatment regarding response to therapy. This will be assessed by compliance with therapy (as monitored by a smart card within the positive pressure machine), improvement in sleepiness as measured by the Epworth Sleepiness Score, and change in quality of life as measured by the Sleep Apnea Quality of Life Index (SAQLI) a validated quality of life instrument specific to sleep apnea.
In addition, in those who demonstrated persistent central apneas after 12 weeks of CPAP therapy, and were randomized to CPAP or ASV, a third and final sleep study will be done to assess the residual apnea-hypopnea index (the number of respiratory events divided by the number of hours of sleep) on therapy. In those randomized to CPAP who have a persistent poor clinical response associated with an abnormal residual AHI after 24 weeks of treatment, a further 12 week trial of ASV will be undertaken to assess whether it offers any benefit.
In addition to assessing the effect of treatment, the original diagnostic polysomnogram of all patients with complex sleep apnea will be analyzed to determine if there are any polysomnographic features that could be utilized to predict complex sleep apnea before CPAP is applied, (for example: 1) evidence of mixed apneas; or 2) a component of central apneas in addition to the predominant pattern of OSA.)
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Manitoba
-
Winnipeg, Manitoba, Canada
- Miseracordia Sleep Disorders Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient with obstructive sleep apnea who develop central sleep apnea once treated with CPAP
Exclusion Criteria:
- Inability to give informed consent, inability to tolerate positive pressure ventilation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: CPAP
Continuous Positive Airway Pressure
|
All patients will initially be treated with CPAP for 12 weeks as part of usual clinical treatment for sleep apnea.
A sleep study will be conducted after this and prior to randomization into the study.
If this repeat sleep study demonstrates persistent central sleep apnea, patients will be randomized into 2 study groups.
Group 1 - CPAP for 24 weeks.
Group 2 - first 12 weeks CPAP (Continuous Positive Airway Pressure.
Next 12 weeks - (ASV) Adaptive Servo ventilation.
If the treatment is not working well at 12 weeks the participant/patients have the option of switching to the alternate treatment.
Patients will be notified if they are to be switched to ASV.
Participants will be asked to fill in the Epworth Sleepiness Score Questionnaire and Sleep Apnea Quality of Life Index form at 12 and 24 weeks.
|
ACTIVE_COMPARATOR: Adaptive Servo-Ventilator
Non-invasive positive pressure ventilator that applies a constant expiratory pressure, as well as a variable inspiratory pressure.
|
All patients will initially be treated with CPAP for 12 weeks as part of usual clinical treatment for sleep apnea.
A sleep study will be conducted after this and prior to randomization into the study.
If this repeat sleep study demonstrates persistent central sleep apnea, patients will be randomized into 2 study groups.
Group 1 - CPAP for 24 weeks.
Group 2 - first 12 weeks CPAP (Continuous Positive Airway Pressure.
Next 12 weeks - (ASV) Adaptive Servo ventilation.
If the treatment is not working well at 12 weeks the participant/patients have the option of switching to the alternate treatment.
Patients will be notified if they are to be switched to ASV.
Participants will be asked to fill in the Epworth Sleepiness Score Questionnaire and Sleep Apnea Quality of Life Index form at 12 and 24 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Resolution of sleep apnea
Time Frame: 24 weeks
|
As measured by the apnea-hyponea index
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of life
Time Frame: 24 weeks
|
As measured by Epworth Sleepiness Scale and Sleep Apnea Quality of Life Index
|
24 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- B2010:026
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sleep Apnea
-
ResMedCRI-The Clinical Research Institute GmbH; University Hospital RegensburgCompletedObstructive Sleep Apnea | Central Sleep Apnea | Mixed Sleep Apnea | Complex Sleep ApneaSwitzerland, Spain, Denmark, Portugal, France, Germany
-
ResMedCompletedObstructive Sleep Apnea | Central Sleep Apnea (Diagnosis) | Chronic Opioid UseUnited States
-
Medtronic - MITGCompletedObstructive Sleep Apnea | Sleep Apnea | Sleep-Disordered Breathing | Central Sleep ApneaUnited States
-
ResMedRWTH Aachen UniversityRecruitingObstructive Sleep Apnea | Central Sleep Apnea | Mixed Sleep ApneaGermany
-
Somnarus IncCompletedObstructive Sleep Apnea | Cheyne-Stokes Respiration | Central Sleep Apnea | Mixed Sleep ApneaUnited States
-
University of California, Los AngelesRecruiting
-
Brigham and Women's HospitalCompletedObstructive Sleep Apnea (OSA)United States
-
The Hospital for Sick ChildrenRecruitingObstructive Sleep Apnea | Hypoventilation | Central Sleep ApneaCanada
-
The Hospital for Sick ChildrenCompleted
-
Cryosa, Inc.Active, not recruitingObstructive Sleep Apnea of AdultPanama, Paraguay
Clinical Trials on Non-invasive positive pressure ventilator
-
Assiut UniversityUnknownChest--DiseasesEgypt
-
Hadassah Medical OrganizationUnknownPneumonia | Chronic Obstructive Pulmonary Disease | Neuromuscular Diseases | Respiratory Insufficiency | Pulmonary EdemaIsrael
-
ResMedRoyal Brompton & Harefield NHS Foundation TrustCompletedNeuromuscular Disease | Chest Wall Disorder | Nocturnal HypoventilationUnited Kingdom
-
University Hospital Inselspital, BerneCompletedNoninvasive Ventilation | Hemodynamics | Heart Function Tests | Circulatory and Respiratory Physiological PhenomenaSwitzerland
-
ResMedRoyal Brompton & Harefield NHS Foundation TrustWithdrawnChronic Obstructive Pulmonary Disease | Respiratory Failure | Obesity Hypoventilation Syndrome | Neuromuscular Disease | Chest Wall DisorderUnited Kingdom
-
Assistance Publique - Hôpitaux de ParisTerminatedVaso-occlusive Crisis | Sickle Cell-hemoglobin SS DiseaseFrance
-
ResMedRoyal Brompton & Harefield NHS Foundation TrustCompletedNeuromuscular Disease | Chest Wall DisorderUnited Kingdom
-
University of Sao Paulo General HospitalUnknownMounier-Kuhn SyndromeBrazil
-
Duke UniversityCompleted
-
Chinese Pulmonary Vascular Disease Research GroupCompletedObstructive Sleep Apnea | Coronary Heart DiseaseChina